Isoform Positions

Isoform Protein Position Transcript Position Chromosomal Position (HG38) Chromosomal Position (HG19)
IC2839885417;85418;85419 chr2:178560940;178560939;178560938chr2:179425667;179425666;179425665
N2AB2675780494;80495;80496 chr2:178560940;178560939;178560938chr2:179425667;179425666;179425665
N2A2583077713;77714;77715 chr2:178560940;178560939;178560938chr2:179425667;179425666;179425665
N2B1933358222;58223;58224 chr2:178560940;178560939;178560938chr2:179425667;179425666;179425665
Novex-11945858597;58598;58599 chr2:178560940;178560939;178560938chr2:179425667;179425666;179425665
Novex-21952558798;58799;58800 chr2:178560940;178560939;178560938chr2:179425667;179425666;179425665
Novex-3NoneNone chr2:Nonechr2:None

Information

  • RefSeq wild type amino acid: I
  • RefSeq wild type transcript codon: ATT
  • RefSeq wild type template codon: TAA
  • Domain: Ig-143
  • Domain position: 41
  • Structural Position: 58
  • Q(SASA): 0.2176
  • Predicted PPI site: I

Reported SAVs

SNV RS
DUET
PolyPhen-2
Condel
Rhapsody
REVEL
MVP
Source
MAF
Disease
Zygosity
Site annotation
mCSM PPI
Predicted PPI site
Comments
AFR
AMR
AMS
ASJ
EAS
EUR
FIN
MDE
NFE
SAS
OTH
I/V rs878970622 None 0.437 N 0.395 0.153 None gnomAD-4.0.0 1.59124E-06 None None None None I None 0 0 None 0 0 None 0 0 2.85798E-06 0 0

Saturation Mutagenesis

SAV
AlphaMissense (IC)
AlphaMissense Class (IC)
AlphaMissense (N2AB)
AlphaMissense Class (N2AB)
mCSM
mCSM class
PolyPhen-2
PolyPhen-2 Class
Rhapsody
Rhapsody Class
Condel
Condel Score
Site annotation
mCSM PPI
Predicted PPI site
I/A 0.4456 ambiguous 0.4326 ambiguous -2.192 Highly Destabilizing 0.919 D 0.433 neutral None None None None I
I/C 0.8552 likely_pathogenic 0.8625 pathogenic -1.457 Destabilizing 0.999 D 0.543 neutral None None None None I
I/D 0.9438 likely_pathogenic 0.9375 pathogenic -1.803 Destabilizing 0.996 D 0.727 prob.delet. None None None None I
I/E 0.8619 likely_pathogenic 0.8515 pathogenic -1.671 Destabilizing 0.996 D 0.719 prob.delet. None None None None I
I/F 0.2666 likely_benign 0.2793 benign -1.332 Destabilizing 0.968 D 0.439 neutral N 0.487813286 None None I
I/G 0.8688 likely_pathogenic 0.8586 pathogenic -2.647 Highly Destabilizing 0.996 D 0.705 prob.neutral None None None None I
I/H 0.8859 likely_pathogenic 0.8816 pathogenic -1.82 Destabilizing 0.999 D 0.722 prob.delet. None None None None I
I/K 0.7965 likely_pathogenic 0.7847 pathogenic -1.671 Destabilizing 0.988 D 0.707 prob.neutral None None None None I
I/L 0.113 likely_benign 0.1196 benign -0.937 Destabilizing 0.011 N 0.162 neutral N 0.445704345 None None I
I/M 0.0953 likely_benign 0.0957 benign -0.818 Destabilizing 0.968 D 0.457 neutral N 0.495459835 None None I
I/N 0.7187 likely_pathogenic 0.7005 pathogenic -1.708 Destabilizing 0.995 D 0.729 prob.delet. D 0.542481672 None None I
I/P 0.901 likely_pathogenic 0.8917 pathogenic -1.33 Destabilizing 0.996 D 0.731 prob.delet. None None None None I
I/Q 0.8122 likely_pathogenic 0.8056 pathogenic -1.704 Destabilizing 0.996 D 0.719 prob.delet. None None None None I
I/R 0.7279 likely_pathogenic 0.713 pathogenic -1.225 Destabilizing 0.988 D 0.729 prob.delet. None None None None I
I/S 0.6568 likely_pathogenic 0.637 pathogenic -2.413 Highly Destabilizing 0.984 D 0.606 neutral D 0.530618388 None None I
I/T 0.2796 likely_benign 0.2704 benign -2.137 Highly Destabilizing 0.946 D 0.496 neutral D 0.539186309 None None I
I/V 0.0992 likely_benign 0.1055 benign -1.33 Destabilizing 0.437 N 0.395 neutral N 0.504968866 None None I
I/W 0.8627 likely_pathogenic 0.859 pathogenic -1.505 Destabilizing 0.999 D 0.708 prob.delet. None None None None I
I/Y 0.7282 likely_pathogenic 0.7365 pathogenic -1.271 Destabilizing 0.988 D 0.562 neutral None None None None I

Titin has multiple isoforms, the longest being the theoretical IC (inferred complete) isoform which contains all 363 in-frame titin exons. Here all isoform positions have been mapped onto the IC sequence, with an exception being the C-terminal of the much shorter novex-3 isoform. This contains the out of frame exon 48 which cannot be mapped to the other isoforms.